AU2015222887B2 - 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors - Google Patents

9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors Download PDF

Info

Publication number
AU2015222887B2
AU2015222887B2 AU2015222887A AU2015222887A AU2015222887B2 AU 2015222887 B2 AU2015222887 B2 AU 2015222887B2 AU 2015222887 A AU2015222887 A AU 2015222887A AU 2015222887 A AU2015222887 A AU 2015222887A AU 2015222887 B2 AU2015222887 B2 AU 2015222887B2
Authority
AU
Australia
Prior art keywords
methyl
indol
dimethylisoxazol
amine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015222887A
Other languages
English (en)
Other versions
AU2015222887A1 (en
Inventor
Angelo AGUILAR
Irfan A. Asangani
Longchuan Bai
Arul Chinnaiyan
Yang Hu
Liu Liu
Ruijuan LUO
Donna Mceachern
Jennifer Lynn Meagher
Xu RAN
Jeanne STUCKEY
Duxin Sun
Shaomeng Wang
Bo WEN
Ting ZHAO
Yujun Zhao
Bing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2015222887A1 publication Critical patent/AU2015222887A1/en
Application granted granted Critical
Publication of AU2015222887B2 publication Critical patent/AU2015222887B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015222887A 2014-02-28 2015-02-27 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors Ceased AU2015222887B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461946501P 2014-02-28 2014-02-28
US61/946,501 2014-02-28
US201461950406P 2014-03-10 2014-03-10
US61/950,406 2014-03-10
US201462031640P 2014-07-31 2014-07-31
US62/031,640 2014-07-31
US201462048388P 2014-09-10 2014-09-10
US62/048,388 2014-09-10
PCT/US2015/017908 WO2015131005A1 (en) 2014-02-28 2015-02-27 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors

Publications (2)

Publication Number Publication Date
AU2015222887A1 AU2015222887A1 (en) 2016-09-08
AU2015222887B2 true AU2015222887B2 (en) 2019-06-27

Family

ID=52706277

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015222887A Ceased AU2015222887B2 (en) 2014-02-28 2015-02-27 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors

Country Status (7)

Country Link
US (2) US9580430B2 (cg-RX-API-DMAC7.html)
EP (1) EP3110818B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017511801A (cg-RX-API-DMAC7.html)
CN (1) CN107074861A (cg-RX-API-DMAC7.html)
AU (1) AU2015222887B2 (cg-RX-API-DMAC7.html)
CA (1) CA2940554A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015131005A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
JP6243003B2 (ja) 2013-03-15 2017-12-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EP3110818B1 (en) * 2014-02-28 2019-10-23 The Regents of The University of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
ES2942723T3 (es) 2014-04-23 2023-06-06 Incyte Holdings Corp 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
WO2016138332A1 (en) * 2015-02-27 2016-09-01 The Regents Of The University Of Michigan 9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors
US9725449B2 (en) * 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
WO2017133681A1 (zh) * 2016-02-05 2017-08-10 正大天晴药业集团股份有限公司 溴区结构域蛋白抑制剂的三环类化合物及其制备、药物组合物和用途
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
RU2743432C2 (ru) * 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
CN109311900A (zh) 2016-04-06 2019-02-05 密执安大学评议会 用于配体依赖性靶蛋白质降解的单官能中间体
AU2017250076B2 (en) 2016-04-12 2021-07-22 The Regents Of The University Of Michigan Bet protein degraders
US20170362206A1 (en) 2016-06-16 2017-12-21 Denali Therapeutics Inc. Compounds, compositions, and methods
RS64274B1 (sr) 2016-06-20 2023-07-31 Incyte Corp Kristalni čvrsti oblici bet inhibitora
EP3512853B1 (en) 2016-09-13 2020-12-23 The Regents of The University of Michigan Fused 1,4-diazepines as bet protein degraders
AU2017326171B2 (en) 2016-09-13 2021-12-09 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
MX2020000693A (es) 2017-07-18 2020-07-29 Nuvation Bio Inc Compuestos de 1,8-naftiridinona, y usos de los mismos.
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
CN109223792A (zh) * 2018-04-24 2019-01-18 李明霞 一种治疗骨关节炎的药物组合物及其制备方法
KR20210038921A (ko) 2018-07-25 2021-04-08 치아타이 티안큉 파마수티컬 그룹 주식회사 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도
JP2022509534A (ja) 2018-10-30 2022-01-20 ニューベイション・バイオ・インコーポレイテッド Ｂｅｔ阻害剤としてのヘテロ環式化合物
US20220002816A1 (en) * 2018-11-13 2022-01-06 Center For Cancer Research & Therapeutic Development, Clark Atlanta University Identification of jund target genes for inhibition of prostate cancer cell growth
KR102329235B1 (ko) 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
WO2020106059A1 (ko) * 2018-11-21 2020-05-28 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
JP2022523473A (ja) 2019-01-18 2022-04-25 ニューベイション・バイオ・インコーポレイテッド １，８－ナフチリジジノン化合物およびそれらの使用
JP2022517419A (ja) 2019-01-18 2022-03-08 ニューベイション・バイオ・インコーポレイテッド アデノシンアンタゴニストとしてのヘテロ環式化合物
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
EP3976584A1 (en) * 2019-05-29 2022-04-06 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2021003310A1 (en) 2019-07-02 2021-01-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
CN112851679B (zh) * 2019-11-28 2022-03-25 广东医科大学 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用
CN112851678B (zh) * 2019-11-28 2022-04-19 广东医科大学 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤转移作用
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
CN113018301A (zh) * 2019-12-09 2021-06-25 中国科学院大连化学物理研究所 JQ1与Erlotinib组合物在制备治疗肝癌药物中应用和治疗肝癌药物
IL293811A (en) * 2019-12-18 2022-08-01 Univ Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11814388B1 (en) 2020-08-28 2023-11-14 Ferris State University Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers
CN114044754A (zh) * 2021-11-23 2022-02-15 贵州大学 一类5-三氟甲基-4-吡唑衍生物的制备方法及其在抑制肿瘤细胞上的应用
CN115057859B (zh) * 2022-05-10 2023-07-21 中国人民解放军海军军医大学 一类具有抗肿瘤抗真菌活性的化合物及其应用
WO2024099441A1 (en) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Bromodomain and extra-terminal (bet) protein degrader
WO2024233776A1 (en) * 2023-05-09 2024-11-14 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12d mutant
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025230961A1 (en) * 2024-04-29 2025-11-06 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267709A1 (en) * 2007-12-13 2010-10-21 Young Jonathan R Inhibitors of janus kinases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1998011111A1 (en) 1996-09-13 1998-03-19 Yoshitomi Pharmaceutical Industries, Ltd. Thienotriazolodiazepine compounds and medicinal uses thereof
EP1887008B1 (en) 2005-05-30 2021-04-21 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and a medicinal use thereof
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
PL2346837T3 (pl) 2008-06-26 2015-07-31 Resverlogix Corp Sposoby wytwarzania pochodnych chinazolinonu
CN102458405B (zh) 2009-04-22 2017-06-23 雷斯韦洛吉克斯公司 新抗炎剂
DE102009051823A1 (de) 2009-11-04 2011-05-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Einkristallines Schweißen von direktional verfestigten Werkstoffen
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
PL2496582T3 (pl) 2009-11-05 2016-08-31 Glaxosmithkline Llc Benzodiazepinowy inhibitor bromodomeny
DE102009053235A1 (de) 2009-11-06 2011-05-19 Gottwald Port Technology Gmbh Umschlagsystem für ISO-Container mit einer Containerbrücke
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
JP5913292B2 (ja) 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 代謝を調節する組成物および方法
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CN103547152A (zh) 2011-02-23 2014-01-29 西奈山伊坎医学院 溴结构域蛋白的抑制剂作为基因表达的调节剂
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CA2862140C (en) * 2012-01-27 2020-04-21 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
HK1206744A1 (en) 2012-04-20 2016-01-15 Abbvie Inc. Isoindolone derivatives
RU2632915C2 (ru) 2012-06-12 2017-10-11 Эббви Инк. Производные пиридинона и пиридазинона
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
TWI736517B (zh) * 2013-12-24 2021-08-21 美商必治妥美雅史谷比公司 作為抗癌劑之新穎三環化合物
EP3110818B1 (en) * 2014-02-28 2019-10-23 The Regents of The University of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267709A1 (en) * 2007-12-13 2010-10-21 Young Jonathan R Inhibitors of janus kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIM, JONGWON ET AL, "Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders", JOURNAL OF MEDICINAL CHEMISTRY, (2011), 54(20), 7334-7349 *

Also Published As

Publication number Publication date
US9580430B2 (en) 2017-02-28
US20150246923A1 (en) 2015-09-03
CA2940554A1 (en) 2015-09-03
EP3110818B1 (en) 2019-10-23
JP2017511801A (ja) 2017-04-27
WO2015131005A1 (en) 2015-09-03
US20170210761A1 (en) 2017-07-27
US10253044B2 (en) 2019-04-09
EP3110818A1 (en) 2017-01-04
CN107074861A (zh) 2017-08-18
AU2015222887A1 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
AU2015222887B2 (en) 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
TWI760685B (zh) 作為mcl-1抑制劑的大環稠合的吡唑
US11192898B2 (en) MDM2 protein degraders
US11045448B2 (en) Piperidines as covalent menin inhibitors
CN110914265B (zh) 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
CA3036841A1 (en) Fused 1,4-diazepines as bet protein degraders
CA3036834A1 (en) Fused 1,4-oxazepines as bet protein degraders
CA3020541A1 (en) Bet protein degraders
US10307407B2 (en) 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
AU2014249192A1 (en) BET bromodomain inhibitors and therapeutic methods using the same
IL257340B1 (en) Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals
EP3416969A1 (en) Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
US20230257365A1 (en) Small molecule androgen receptor protein degraders
US11046709B2 (en) Fused 1,4-diazepines as BET bromodomain inhibitors
HK40026020A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40026020B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired